title: GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.
abstract: The results of studies investigating the associations between GSTM1 and GSTT1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity (ADIH) risk exhibit much controversy. Therefore, a meta-analysis was performed in order to examine the associations between GST variants and ADIH risk. A total of 451 relevant studies were identified through the digital medical databases Medline, Embase, and CBM published up to October 2012. Thirteen individual case-control studies were eventually recruited for GSTM1 null polymorphism (including 951 ADIH cases, 1,922 controls) and 12 studies for GSTT1 null polymorphism (847 cases, 1,811 controls). Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were appropriately calculated from fixed-effects or random-effects models. Subgroup analyses were stratified by ethnicity and different treatment combinations. The overall ORs of relevant studies that exhibited elevated ADIH risk was significantly associated with GSTM1 null genotypes (OR = 1.36, 95% CI 1.04-1.79), but for the GSTT1 polymorphism, no difference was found (OR = 0.98, 95% CI 0.82-1.18). In the subgroup analyses, the pooled results showed that GSTM1 null allele carriers had a significant association with ADIH risk in East Asians and the patients who used isoniazid (INH) + rifampicin (RMP) + pyrazinamide (PZA) + ethambutol (EMB), or + streptomycin (SM) (HRZES), but the opposite result was observed for patients using HR. Moreover, the GSTT1 null genotype evaluated the susceptibility to ADIH for tuberculosis using HRZ. This meta-analysis provides evidence that there may be an increased risk of ADIH in individuals with null genotypes of GSTM1 in the total population, especially East Asians and patients receiving HRZE or HRZES. However, polymorphisms of the GSTT1 null genotype seem to have no association with susceptibility to ADIH, except for patients receiving HRZ.
authors: School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
authors: C
authors: C
authors: Li
authors: J
authors: J
authors: Long
authors: X
authors: X
authors: Hu
authors: Y
authors: Y
authors: Zhou
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D011110:Polymorphism, Genetic; D014376:Tuberculosis / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents; D005982:Glutathione Transferase; C413545:glutathione S-transferase T1
references: Zhonghua Jie He He Hu Xi Za Zhi. 2009 Apr;32(4):266-9
references: 19576039
references: J Clin Pharm Ther. 2012 Dec;37(6):712-8
references: 22845549
references: PLoS One. 2012;7(10):e47769
references: 23082213
references: Curr Opin Allergy Clin Immunol. 2001 Aug;1(4):317-25
references: 11964707
references: Carcinogenesis. 1998 Aug;19(8):1329-32
references: 9744524
references: Am Rev Respir Dis. 1972 Sep;106(3):357-65
references: 5080707
references: Ann Intern Med. 1976 Feb;84(2):181-92
references: 766682
references: J Clin Pharm Ther. 2012 Oct;37(5):588-93
references: 22335459
references: Pharmacogenomics. 2007 May;8(5):435-42
references: 17465707
references: Thorax. 1998 Jul;53(7):536-48
references: 9797751
references: Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52
references: 17021358
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Ann Intern Med. 1997 Nov 1;127(9):820-6
references: 9382404
references: Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):1-8
references: 17269890
references: Liver Int. 2008 Jul;28(6):835-9
references: 18397238
references: J Hepatol. 2007 Jul;47(1):128-34
references: 17400324
references: Mutat Res. 1998 Jul 17;403(1-2):45-53
references: 9726005
references: J Int Med Res. 2010 May-Jun;38(3):977-86
references: 20819434
references: Clin Pharmacol Ther. 2003 May;73(5):435-55
references: 12732844
references: J Lab Clin Med. 1986 Sep;108(3):190-8
references: 3091744
references: Mol Diagn Ther. 2012 Aug 1;16(4):241-50
references: 22788240
references: Clin Chim Acta. 2013 Jan 16;415:215-9
references: 23099118
references: Biometrics. 1994 Dec;50(4):1088-101
references: 7786990
references: Am Rev Respir Dis. 1978 Sep;118(3):461-6
references: 707874
references: Tuberculosis (Edinb). 2010 Jan;90(1):39-43
references: 20036620
references: J Gastroenterol Hepatol. 2001 Sep;16(9):1033-7
references: 11595069
references: Biochem J. 1991 Mar 1;274 ( Pt 2):409-14
references: 1848757
references: Annu Rev Biochem. 1983;52:711-60
references: 6137189
references: Mem Inst Oswaldo Cruz. 2011 Sep;106(6):716-24
references: 22012226
references: Hepatology. 1996 Jun;23(6):1448-55
references: 8675163
references: In Vivo. 2011 Sep-Oct;25(5):803-12
references: 21753138
references: J Gastroenterol Hepatol. 2008 Feb;23(2):192-202
references: 17995946
references: J Hum Genet. 2007;52(2):166-171
references: 17180579
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: J Clin Pharm Ther. 2010 Aug;35(4):465-70
references: 20853551
references: Science. 1983 Apr 29;220(4596):472-7
references: 6836290
references: Int J Tuberc Lung Dis. 2008 Sep;12(9):994-1002
references: 18713495
references: Biochim Biophys Acta. 1986 Nov 7;874(1):1-12
references: 3768372
references: J Pharmacol Exp Ther. 1973 Oct;187(1):211-7
references: 4746329
references: Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62
references: 12588714
references: Eur J Cancer. 2005 May;41(7):980-9
references: 15862746
references: Cancer Sci. 2003 May;94(5):448-52
references: 12824892
references: Cent Eur J Public Health. 2010 Dec;18(4):237
references: 21361110
references: BMJ. 2007 Nov 3;335(7626):914-6
references: 17974687
references: Clin Pharmacol Ther. 2000 Apr;67(4):432-7
references: 10801254
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120